Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
复制标题
定义和管理COVID-19相关的肺曲霉病：2020年ECMM/ISHAM研究和临床指南共识标准。
DOI：
10.1016/s1473-3099(20)30847-1
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Infectious Disease Canada
中科院分区：
文献类型：
--
作者：
Koehler P;Bassetti M;Chakrabarti A;Chen SCA;Colombo AL;Hoenigl M;Klimko N;Lass-Flörl C;Oladele RO;Vinh DC;Zhu LP;Böll B;Brüggemann R;Gangneux JP;Perfect JR;Patterson TF;Persigehl T;Meis JF;Ostrosky-Zeichner L;White PL;Verweij PE;Cornely OA;European Confederation of Medical Mycology;International Society for Human Animal Mycology;Asia Fungal Working Group;INFOCUS LATAM/ISHAM Working Group;ISHAM Pan Africa Mycology Working Group;European Society for Clinical Microbiology;Infectious Diseases Fungal Infection Study Group;ESCMID Study Group for Infections in Critically Ill Patients;Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy;Medical Mycology Society of Nigeria;Medical Mycology Society of China Medicine Education Association;Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology;Association of Medical Microbiology;Infectious Disease Canada
严重急性呼吸系统综合征冠状病毒2型直接损害气道上皮，使曲霉菌入侵。COVID-19相关肺曲霉病的报告引发了人们对它恶化COVID-19病程和增加死亡率的担忧。此外，还报告了由耐唑曲霉菌引起的COVID-19相关肺曲霉病的首批病例。本文构成了关于定义和管理COVID-19相关肺曲霉病的共识声明，由专家编写并得到医学真菌学会的认可。根据样本有效性和诊断确定性，建议将COVID-19相关肺曲霉病定义为可能、很可能或已证实。推荐的一线治疗是伏立康唑或艾沙康唑。如果唑类耐药是一个问题，那么脂质体阿替霉素B是首选药物。我们的目标是为临床研究提供定义，并为COVID-19相关肺曲霉病的诊断和治疗的临床管理提供最新建议。
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.